Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Juneteenth
Donald Trump
Artificial Intelligence
War
Social Media
World Cup
US Politics
US Immigration
Senate
Immigration
Soccer
Republican Party
Published • loading... • Updated

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

Summary by biopharmadive.com
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.

1 Articles

All
Left
Center
1
Right
biopharmadive.combiopharmadive.com
Center

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Tuesday, June 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

23andMe

23andMe

United States

United States

News
For You
SearchBlindspotLocal